RESEARCH ARTICLE


Cholesteryl Ester Transfer Protein Gene and Effectiveness of Lipid Lowering of Atorvastatin



Genovefa Kolovou1, *, Constantinos Mihas2, Katherine Anagnostopoulou3, Vana Kolovou3, Vasiliki Giannakopoulou1, Peggy Kostakou1, Marianna Stamatelatou1, Sophie Mavrogeni1, Dimitrios Degiannis3, Dimitri P. Mikhailidis4
1 1st Cardiology Department, Onassis Cardiac Surgery Center Athens, Greece
2 Internal Medicine Department, Kimi General Hospital, Kimi, Greece
3 Molecular Immunology Laboratory, Onassis Cardiac Surgery Center Athens, Greece
4 Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital campus, University College London Medical School, University College London (UCL), London, UK


© Kolovou et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Onassis Cardiac Surgery Center 356 Sygrou Ave 176 74 Athens, Greece; Tel: +30 210 9493520; Fax: +30 210 9493336; E-mail: genovefa@kolovou.com


Abstract

Cholesteryl ester transfer protein (CETP) plays a key role in lipid metabolism. Thus, variations in the CETP gene may be clinically relevant.

Newly started atorvastatin users (n=212) were genotyped for CETP genetic variants (TaqIB and I405V). Homozygotes for B1 allele of TaqIB polymorphism had lower plasma high density lipoprotein cholesterol (HDL-C) compared with B1B2 or B2B2 genotypes (p=0.03, for each). Homozygotes for I allele of I405V polymorphism had lower plasma HDL-C compared with IV or VV genotypes (p=0.001, for each). In the whole population, the B1 carriers increased HDL-C levels by 4% after atorvastatin treatment, compared with B2 carriers, where a 4% decrease occurred (p=0.03). Also homozygotes for B1 allele decreased triglyceride levels to a lesser, though not significant, degree compared to B1B2 or B2B2 genotypes.

CETP TaqIB or I405V polymorphisms seem to modify the lipid lowering response to atorvastatin treatment. This knowledge may help design more effective hypolipidaemic treatment.

Keywords: Atorvastatin, cholesteryl ester transfer protein, genetic polymorphisms, lipid profile..